Updates in the Treatment of HR+/HER2- Breast Cancer - Episode 8
Panelists discuss recent data on other selective estrogen receptor degraders (SERDs) and their implications in the treatment of HR+/HER2– breast cancer.
Video content above is prompted by the following:
Dr. Bardia to Dr. Teplinsky: Please briefly mention recent data on other SERDs: